secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARS Pharmaceuticals, Inc. (SPRY)
CIK:        0001671858
Form:       8-K
Filed at:   2023-05-15T23:59:59+00:00
Accession:  0000950170-23-021996
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ARS Pharma neffy FDA Panel Vote 'Favorable'; Q1 Net Loss $15.0M, Cash $264.5M
-----------------------------------------------------------------------------

- FDA advisory committee voted 16:6 (adults) and 17:5 (children) that neffy benefit-risk is favorable.
- PDUFA target action date anticipated mid-2023; NDA and MAA under review in US and EU.
- Cash $264.5M, sufficient for at least three years including planned neffy launch.
- Net loss $15.0M for Q1 2023; R&D $6.6M, G&A $12.2M.
- Commercial launch prep underway with planned 125-person salesforce.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671858/000095017023021996/0000950170-23-021996-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671858/000095017023021996/spry-20230515.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-021996

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer